Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value
Friday, March 2, 2018, 10:00 AM – 4:00 PM

Agenda
Lunch available at 12:15 PM
Preservation Park, 1233 Park Way, Oakland, CA 94612

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 am—10:00 am</td>
<td>Registration</td>
</tr>
</tbody>
</table>
| 10:00 am—10:15 am| Meeting Convened and Opening Remarks:
Steven Pearson, MD, MSc, President, ICER
Paul Heidenreich, MD, MS, Chair, CTAF |
| 10:15 am—11:15 am| Presentation of the Evidence
Jeffrey A. Tice, MD, University of California, San Francisco
Melanie D. Whittington, PhD, University of Colorado |
| 11:15 am—11:45 am| Manufacturer Comments and Discussion                                      |
| 11:45 am—12:15 pm| Public Comments and Discussion
**Members of the public pre-registered to deliver oral remarks** |
| 12:15 pm—1:00 pm| Lunch
Lunch will be provided for meeting attendees |
| 1:00 pm—2:15 pm| CTAF Panel Q&A with Clinical Experts
CTAF Deliberation and Vote of Clinical Effectiveness and Value
ICER staff and clinical experts are available for questions from the Council during deliberation |
| 2:15 pm—3:30 pm| Policy Roundtable                                                         |
| 3:30 pm—4:00 pm| Reflections from CTAF                                                     |
| 4:00 pm        | Meeting Adjourned                                                         |
Meeting Participants

<table>
<thead>
<tr>
<th>Participating Members of the California Technology Assessment Forum (CTAF)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Felicia Cohn, PhD,</strong> <em>Bioethics Director, Kaiser Permanente, Orange County</em>*</td>
</tr>
<tr>
<td><strong>Robert Collyar,</strong> <em>Patient Advocate</em></td>
</tr>
<tr>
<td><strong>Rena K. Fox, MD,</strong> <em>(CTAF vice chair) Professor of Medicine, UCSF</em></td>
</tr>
<tr>
<td><strong>Luanda Grazette, MD, MPH, FACC,</strong> <em>(Associate Professor of Clinical Medicine, USC Keck School of Medicine)</em></td>
</tr>
<tr>
<td><strong>Kimberly Gregory, MD, MPH,</strong> <em>(Vice Chair, Women’s Healthcare Quality and Performance Improvement, Cedars-Sinai Medical Center)</em></td>
</tr>
<tr>
<td><strong>Paul Heidenreich, MD, MS,</strong> <em>(CTAF chair) Professor and Vice Chair for Quality, Clinical Affairs, and Analytics, Stanford University</em></td>
</tr>
<tr>
<td><strong>Jeffrey Hoch, PhD,</strong> <em>(Associate Director, Center for Healthcare Policy and Research, UC Davis)</em></td>
</tr>
</tbody>
</table>

*No relevant conflicts of interest to disclose, defined as more than $10,000 in healthcare company stock or more than $5,000 in honoraria or consultancies during the previous year from health care manufacturers or insurers*

Policy Roundtable Participants

- **Emily Dumler,** Patient Advocate
- **Denise Globe, PhD,** Vice President and Head of Health Economics and Outcomes Research, US Oncology, Novartis Pharmaceuticals
- **Michelle Hermiston, MD, PhD,** Associate Professor, Department of Pediatrics (Hematology/Oncology); Department of Pediatric Hematology/Oncology; Director, Pediatric Immunotherapy Program, UCSF School of Medicine and UCSF Helen Diller Family Comprehensive Care Center
- **Krishna Komanduri, MD,** Kalish Family Chair in Stem Cell Transplantation; Professor of Medicine, Microbiology, and Immunology; Director, Adult Stem Cell Transplant Program, University of Miami Miller School of Medicine and President, American Society for Blood and Marrow Transplantation
- **Jennifer Malin, MD, PhD,** Senior Medical Director, Oncology and Genetics, United Healthcare
- **Rocio Manghani, MPH,** Senior Director, Payer Relations and Market Access, Kite Pharma (A Gilead Company)
- **Kimberly Schuetz,** Patient Advocate
- **John Yao, MD, MPH, MBA, MPA, FACP,** Staff Vice President of Medical Policy, Anthem

Institute for Clinical and Economic Review (ICER) Staff and Consultants

R. Brett McQueen, PhD, Assistant Professor, Dept. of Clinical Pharmacy, Center for Pharmaceutical Outcomes Research, University of Colorado

Molly Morgan, Program and Events Coordinator, ICER

Dan Ollendorf, PhD, Chief Scientific Officer, ICER

Ifeoma Otuonye, MPH, Research Associate, ICER

Steven Pearson, MD, MSc, President, ICER

Matt Seidner, BS, CTAF Program Manager, ICER

Jeffrey Tice, MD, CTAF Senior Medical Advisor

Judith Walsh, MD, MPH, Professor of Medicine and Epidemiology and Biostatistics, University of California San Francisco

Melanie Whittington, PhD, Research Instructor, Dept. of Clinical Pharmacy Center for Pharmaceutical Outcomes Research, University of Colorado